These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19520688)

  • 1. A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.
    Kim YH; Kubota K; Goto K; Yoh K; Niho S; Ohmatsu H; Saijo N; Nishiwaki Y
    Jpn J Clin Oncol; 2009 Sep; 39(9):576-81. PubMed ID: 19520688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
    Kurata T; Hirashima T; Iwamoto Y; Kawaguchi T; Ikeda N; Tsuboi M; Sawa T; Ishiguro T; Aoki T; Kotani Y; Nakagawa K; Fukuoka M
    Lung Cancer; 2012 Jul; 77(1):110-5. PubMed ID: 22306126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
    Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
    Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
    Bajetta E; Stani SC; De Candis D; Zaffaroni N; Zilembo N; Cortinovis D; Aglione S; Mariani L; Formisano B; Bidoli P
    Ann Oncol; 2003 Feb; 14(2):242-7. PubMed ID: 12562651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
    Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
    Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
    Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
    Choy H; Jain AK; Moughan J; Curran W; Whipple G; Demas WF; Ettinger DS
    J Thorac Oncol; 2009 Jan; 4(1):80-6. PubMed ID: 19096311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Takayama K; Ichiki M; Matsumoto T; Ebi N; Akamine S; Tokunaga S; Yamada T; Uchino J; Nakanishi Y
    Oncologist; 2020 Mar; 25(3):208-e417. PubMed ID: 32162814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
    Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
    Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
    Takayama K; Takeshita M; Inoue K; Ichiki M; Fujita M; Harada T; Shiraishi Y; Wataya H; Tokunaga S; Yamada T; Uchino J; Sugio K
    Oncologist; 2020 Aug; 25(8):e1146-e1157. PubMed ID: 32385918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
    Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
    J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
    Kurata T; Tamura K; Yamamoto N; Nogami T; Satoh T; Kaneda H; Nakagawa K; Fukuoka M
    Br J Cancer; 2004 Jun; 90(11):2092-6. PubMed ID: 15150564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
    Favaretto A; Ceresoli GL; Paccagnella A; Barbieri F; Bearz A; Ghiotto C; Oniga F; Schiavon S; Frustaci S; Villa E
    Ann Oncol; 2000 Nov; 11(11):1421-6. PubMed ID: 11142482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.